There are no curative options in patients with unresectable metastases from colorectal cancer (mCRC), but treatment with systemic chemotherapy improves overall survival (OS).1 Therapeutic options currently available rely on three cytotoxic chemotherapies, fluoropyrimidine, oxaliplatin, and irinotecan, associated with targeted-therapy anti–epidermal growth factor receptor (EGFR) or anti–vascular endothelial growth factor (VEGF). This evidence concerns the gene EGFR and colorectal cancer.